La cadena de opciones muestra datos clave de las opciones de acciones de DiaMedica Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para DiaMedica Therapeutics..

DiaMedica Therapeutics (NASDAQ:DMAC) Bolsa, Cadena de Opciones

DiaMedica Therapeutics

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics Inc

Press Releases

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

Small Cap

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

DMAC

AC Immune

Altimmune

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Annexon

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Avalo Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Design Therapeutics

enGene Holdings

ETHZilla

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

Invivyd

Kamada

Korro Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

PureTech Health plc - American Depositary Shares

PureTech Health

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Solid Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Comments

DiaMedica Therapeutics

DiaMedica Therapeutics (DMAC) Opciones

DiaMedica Therapeutics (NASDAQ:DMAC) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL